Ypsomed

Company Overview

Founded in 1984 and headquartered in Burgdorf, Switzerland, Ypsomed AG is a medical technology company focused on developing, manufacturing and selling injection pens for global pharmaceutical and biotech companies. The company operates in two segments: Delivery Devices and Diabetes Direct Business.

• The Delivery Devices segment’s products include pen systems, pen needles, infusion sets and other injection molding products sold globally by leading pharmaceutical and biotech companies under their brand names.

• The Diabetes Direct business sells and trades devices for self-monitoring blood glucose levels and infusion pumps, accessories and other day-to-day items for people with diabetes. It offers insulin pumps, injection systems and pen needles for treating diabetes, growth disorders, infertility and other therapeutic areas, as well as pen needles under the mylife Diabetes Care brand. These products are marketed directly to diabetes patients, doctors, specialist personnel or health insurance providers.

Ypsomed AG markets its products through biotech and pharmaceutical partners, as well as through its distribution network and independent distributors. It lists nearly 2,200 global employees.

Financial Highlights (FY 2023)

Company's Business Segments

• Diabetes Care : Ypsomed Diabetes Care offer a Modular, Customisable solution for a Diabetes Therapy Management that is both Flexible, Expandable.
• Delivery Systems : Ypsomed Delivery Systems provides a complete range of Technologies, Services for reliable and user-friendly Injection Systems as well as Digital Health Solutions for Self-medication.